BCEAO releases $ 6 billion for West African economies

The BCEAO has just made a liquidity injection of 3350 billion FCFA ($ 6 billion) at a fixed rate of 2% in favor of several banks of the UMOA. A total of 87 financial institutions participated in the operation. The Central Bank of West African States (BCEAO) made a further injection of liquidity to its member countries last week. In total, 3350 billion FCFA ($ 6 billion) were disbursed by the institution.

During the auction on September 14, 87 banks in the sub-region obtained an injection of liquidity at a fixed rate of 2%. With more than 1000 billion FCFA ($ 1.8 billion), it is the Ivory Coast which obtained the most important financing, ie 31% of the funds injected.

It is followed by Senegal with more than 580 billion FCFA ($ 1 billion), Mali with 466 billion FCFA (835 million $), Benin with 434.5 billion FCFA (777 million $) and Burkina Faso with 318 billion FCFA. ($ 569 million). Niger with 241.6 billion FCFA ($ 432 million), Togo with 219 billion FCFA (…

France tightens access to chloroquine in pharmacies faced with the risk of shortage

In a press release published on Thursday, March 26 on its website, the National Agency for the Safety of Medicines and Health Products (ASNM) tells pharmacists the rules to follow regarding the delivery of hydroxychloroquine, recommended by certain infectiologists in the treatment coronavirus. An update that follows the decree framing the conditions of prescription of the drug.

France tightens access to chloroquine in pharmacies faced with the risk of shortage

Haro on hydroxychloroquine… Since Professor Didier Raoult, infectious disease specialist in Marseille, has presented it as the remedy for Covid-19, this molecule, marketed under the name of Plaquenil, has aroused an unusual craze. To the point that the Ministry of Health and the National Medicines Agency (ASNM) - which manages the famous marketing authorizations (AMM) - fear a shortage whose consequences would be dramatic for the tens of thousands of French people who treat their chronic pathologies (lupus, rheumatoid arthritis) with this drug.

To limit the danger, the Minister of Health Olivier VĂ©ran therefore issued a decree strictly governing the prescription of Plaquenil as well as another antiviral, Kaletra, also experienced in the treatment of coronavirus. Came into force on Thursday, the text provides that “the pharmaceutical specialty PLAQUENIL © and preparations based on hydroxychloroquine can only be dispensed by pharmacies as part of an initial prescription exclusively from specialists in rheumatology, internal medicine, dermatology, nephrology, neurology or pediatrics or as part of a refill from any doctor ”.

Under this text, only indoor pharmacies in healthcare establishments are now authorized to deliver Plaquenil "outside of marketing authorization", that is to say outside of its usual indications. What makes any prescription impossible for the liberal doctors, within the framework of the treatment of the coronavirus, for example.

On the other hand, the decree authorizes the prescription of Plaquenil outside MA, in the treatment of coronavirus, but it is reserved for hospital doctors: “Hydroxychloroquine and the combination lopinavir / ritonavir can be prescribed, dispensed and administered under the responsibility of a doctor to patients affected by Covid-19, in the health establishments which take charge of them, as well as, for the continuation of their treatment if their condition allows it and with the authorization of the initial prescriber, at home. ”

A few hours after the publication of the decree in the Official Journal, the National Medicines Agency has stepped up to clarify to city pharmacists the conditions for dispensing the drug. In a press release published on its website, the organization reports “difficulties in accessing city pharmacies to Plaquenil and Kaletra treatments for the chronically ill” and reminds pharmacists that to date neither Plaquenil nor Kaletra have no indication in the management of COVID-19 in the city. There is therefore no justification for their prescription in this indication ”. It remains to be seen whether this warning will be sufficient to avoid the shortage of hydroxychloroquine that threatens patients with chronic pathologies, particularly in the city of Lyon.